MILLION

Heart failure patients globally at every given moment​

SCROLL DOWN TO LEARN MORE

Millions of fatalities...

Lives that can be saved with proper early detection and warning​

Billion

US Dollars in hospitalization costs in the US alone​

Costs that can be saved with proper early detection and warning​

existing solutions don't cut it

Clinical parameters monitoring​

Implantable devices​

Non-invasive monitoring​

• Following weight, blood pressure, etc. is not nearly sensitive enough for monitoring of lung congestion in heart failure patients​

• There are no methods for determination of patient’s deterioration at very early stage. Results: prevention of the deterioration and hospitalization is dramatically less efficient hospitalization is impossible​
•   No clinical indication for implantation for majority of Heart Failure patients

• Very expensive device

• Not suitable for mass monitoring

• Traditional transthoracic impedance measurement is not sensitive enough to enable prediction​
• Radar Technologies are not supported with enough clinical evidence about efficacy of technology 

SOLUTION​

Revolutionary non-invasive, early detection device​

EDEMA GUARD MONITOR​

Registering accurately the most minuscule changes in lung fluid content allowing life-saving pre-emptive treatment at a very early stage​

seconds​

Measurement time while brushing  teeth in the morning​

Monitoring patient’s lung fluid

by Edema Guard Monitor.​

Our device provides immediate results that will be  displayed on the device and sent to the cardiologist when a medication adjustment is required​

ABOUT US​

Relevant scientific interviews and articles​

We are a group of scientists and business people who strive to make a life-changing impact on patients suffering from heart failure lung edema.​

With over 15 years of research and development we now have the solution that can literally revolutionize millions of HF patients' lives by enabling them to self-monitor their lung edema state and detect small changes at an even earliest stage.

American College of Cardiology (ACC)

Interview on Impedence HF Trial with Prof. Michael Kleiner Shochat from CARDIOSET​

2016

Duke Clinical Research Institute

Interview with Prof. Michael Kleiner Shochat from CARDIOSET

2016

Clinical Trials Results TV

Interview  with Prof. Michael Kleiner Shochat from CARDIOSET

2016

Selected articles​

New Israeli Development will save lives​

Monitoring device for for better HF prediction outcomes measuring lung fluid

Derivation of baseline lung impedance in chronic heart failure patient

Method for Expedient Detection and  Convenient Monitoring of Pleural Effusion

Novel method for the preclinical detection of acute heart failure

IMPEDANCE-Guided Pre-emptive Treatment in Chronic Heart Failure

Prediction of cardiogenic pulmonary edema onset by monitoring right lung impedance

clinical trials​

prevention

of heart failure hospitalizations​

Potentially saving millions of lives and billions in hospitalization costs​